Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study

References

• Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–10. doi:10.1158/1078-0432.CCR-13-3271.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science. 2015;348(6230):124–128. doi:10.1126/science.aaa1348.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Ciuleanu T-E, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018 May 31;378(22):2093–2104. doi:10.1056/NEJMoa1801946. Epub 2018 Apr 16.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immuno Ther Cancer. 2019 Feb 27;7(1):57. doi:10.1186/s40425-019-0527-y.
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018 Jan 5;359(6371):91–97. doi:10.1126/science.aan3706.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–2520. doi:10.1056/NEJMoa1500596.
   PubMed Web of Science ®Google Scholar
• Viale G, Trapani D, Curigliano G. Mismatch repair deficiency as a predictive biomarker for immunotherapy efficacy. Biomed Res Int. 2017;4719194:2017.
   Google Scholar
• Dai Y, Sun C, Feng Y, Sun C, Jia Q, Zhu B. Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma. J Cell Mol Med. 2018 May 31;22:3979–3986. doi:10.1111/jcmm.13678. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, Omlin A. Multiple primary tumours: challenges and approaches, a review. ESMO Open. 2017 May 2;2(2):e000172. doi:10.1136/esmoopen-2017-000172. eCollection 2017.
   PubMed Web of Science ®Google Scholar
• Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D’Andrea AD, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7(12):13587–13598. doi:10.18632/oncotarget.v7i12.
   PubMedGoogle Scholar
• Pembrolizumab in advanced BRCA-mutated breast cancer. Identifier: NCT03025035. [ accessed 2019 Mar 9]. https://clinicaltrials.gov/ct2/show/NCT03025035.
   Google Scholar
• Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005 Jan 10;23(2):276–292. doi:10.1200/JCO.2005.10.042.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Bersanelli M, Buti S, Gambale E, Atzori F, Zoratto F, Parisi A, Brocco D, Pireddu A, Cannita K et al. Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study. Immunotherapy. 2018 Jun;10(8):643–655. doi:10.2217/imt-2017-0167.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Bersanelli M, Ficorella C, Buti S. Family history of cancer and DNA damage response genes: two sides of the same coin? Thorac Cancer. 2019 Feb;10(2):401. doi:10.1111/1759-7714.12926.
   PubMed Web of Science ®Google Scholar
• Ogawa H, Kato I, Tominaga S. Family history of cancer among cancer patients. Jpn J Cancer Res GANN. 1985;76:113–118.
   PubMedGoogle Scholar
• Gaughan EM, Cryer SK, Yeap BY, Jackman DM, Costa DB. Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations. Lung Cancer. 2013 Mar;79(3):193–197. doi:10.1016/j.lungcan.2012.12.002. Epub 2012 Dec 27.
   PubMed Web of Science ®Google Scholar
• Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016 Feb 15;22(4):886–894. doi:10.1158/1078-0432.CCR-15-1136.
   PubMed Web of Science ®Google Scholar
• Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018 Mar 1;4(3):374–378. doi:10.1001/jamaoncol.2017.2925.
   PubMed Web of Science ®Google Scholar
• Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, Nagata K, Nakagawa A, Otsuka K, Uehara K, et al. Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study. J Thorac Oncol. 2017 Dec;12(12):1798–1805. doi:10.1016/j.jtho.2017.08.022. Epub 2017 Sep 20.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R. Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients. Clin Lung Cancer. 2019 Feb 21:pii: S1525-7304(19)30025–7. doi:10.1016/j.cllc.2019.02.006. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015 Apr 3;348(6230):124–128. doi:10.1126/science.aaa1348. Epub 2015 Mar 12.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhao J, Wang G, Zhang F, Zhang Z, Zhang F, Zhang Y, Dong H, Zhao X, Duan J, et al. Comutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade. Cancer Res. 2018 Nov 15;78(22):6486–6496. doi:10.1158/0008-5472.CAN-18-1814. Epub 2018 Aug 31.
   PubMed Web of Science ®Google Scholar
• Teo MY, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM, Cipolla CK, Bluth MJ, Chaim J, Al-Ahmadie H, et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. J Clin Oncol. 2018 Jun 10;36(17):1685–1694. doi:10.1200/JCO.2017.75.7740. Epub 2018 Feb 28.
   PubMed Web of Science ®Google Scholar
• De Bono J, Goh J, Ojamaa K, Piulats Rodriguez JM, Drake CG, Hoimes CJ, Wu H, Poehlein CH, Antonarakis ES. KEYNOTE-199: pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2018;36(suppl):abstr5007. doi:10.1200/JCO.2018.36.15_suppl.5007.
   Google Scholar
• Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immuno Ther Cancer. 2018 Dec 4;6(1):141. doi:10.1186/s40425-018-0463-2.
   PubMedGoogle Scholar
• Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev. 2018 Sep 1;32(17–18):1105–1140. doi:10.1101/gad.315739.118.
   PubMed Web of Science ®Google Scholar
• Walter FM, Emery J. ‘Coming down the line’– patients’ understanding of their family history of common chronic disease. Ann Fam Med. 2005 Sep-Oct;3(5):405–414. doi:10.1370/afm.368.
   PubMed Web of Science ®Google Scholar
• Nathan PA, Johnson O, Clamp S, Wyatt JC. Time to rethink the capture and use of family history in primary care. Br J Gen Pract. 2016 Dec;66(653):627–628. doi:10.3399/bjgp16X688273.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247. doi:10.1016/j.ejca.2008.10.026.
   PubMed Web of Science ®Google Scholar
• Song JL, Chen C, Yuan JP, Li -J-J, Sun S-R. Family history of cancer other than breast or ovarian cancer in first-degree relatives is associated with poor breast cancer prognosis. Breast. 2017 Apr;32:130–134. doi:10.1016/j.breast.2017.01.016. Epub 2017 Feb 5.
   PubMed Web of Science ®Google Scholar
• Minana B, Cozar JM, Palou J, Unda Urzaiz M, Medina-Lopez RA, Subirá Ríos J, de la Rosa-kehrmann F, Chantada-Abal V, Lozano F, Ribal MJ, et al. Bladder cancer in Spain 2011: population-based study. J Urol. 2014 Feb;191(2):323–328. doi:10.1016/j.juro.2013.08.049.
   PubMed Web of Science ®Google Scholar
• Ciocan D, Barbe C, Aubin F, Granel-Brocard F, Lipsker D, Velten M, Dalac S, Truchetet F, Michel C, Mitschler A, et al. Distinctive features of melanoma and its management in elderly patients: a population-based study in France. JAMA Dermatol. 2013 Oct;149(10):1150–1157. doi:10.1001/jamadermatol.2013.706.
   PubMed Web of Science ®Google Scholar
• Gridelli C, Balducci L, Ciardiello F, Di Maio M, Felip E, Langer C, Lilenbaum RC, Perrone F, Senan S, de Marinis F, et al. Treatment of elderly patients with non-small-cell lung cancer: results of an international expert panel meeting of the italian association of thoracic oncology. Clin Lung Cancer. 2015 Sep;16(5):325–333. doi:10.1016/j.cllc.2015.02.006.
   PubMed Web of Science ®Google Scholar
• Azawi NH, Joergensen SM, Jensen NV, Clark PE, Lund L. Trends in kidney cancer among the elderly in Denmark, 1980–2012. Acta Oncol. 2016;55(Suppl 1):79–84. doi:10.3109/0284186X.2015.1115121.
   PubMedGoogle Scholar
• Mantel N. Chi-square tests with one degree of freedom: extensions of the Mendel-Haenszel procedure. J Am Stat Assoc. 1963;58:690–700.
   Web of Science ®Google Scholar
• Hosmer DW Jr, Lemeshow S. Sturdivant RX applied logistic regression. Third ed. New Jersey: John Wiley & Sons; 2013.
   Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc. 1958;53:457–481. doi:10.1080/01621459.1958.10501452.
   Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1997;17:343–346. doi:10.1016/0197-2456(96)00075-X.
   Google Scholar
• Cox DR. Regression models and life tables (with discussion). J R Stat Soc Ser B. 1972;74:187–200.
   Google Scholar
• International rules for multiple primary cancers ICD-O third edition. Internal Report No.2004/02. Lyon: International Agency for Research on Cancer. IARC (2004).
   Google Scholar